rrMM: Länger progressionsfrei durch IxazomibKatharina ArnheimSpringer2017DOI 10.1007/s15015-017-3448-y
MajesTEC results with teclistamab in RRMMDavid KillockNature Reviews Clinical Oncology2021DOI 10.1038/s41571-021-00553-6
Pembrolizumab, Pomalidomid Und Niedrig Dosiertes Dexamethason Bei rrMMBrigitte SchalhornSpringer2017DOI 10.1007/s15015-017-3676-1
Add-on Daratumumab Not Cost Effective in RRMMAdis International Limited (now part of Wolters Kluwer Health)Adis International Limited (now part of Wolters Kluwer Health)2020DOI 10.1007/s40274-020-6543-9
rrMM: Pomalidomid auch nach Versagen von Lenalidomid wirksamJudith NeumaierSpringer Science and Business Media LLC2021DOI 10.1007/s15015-021-3444-0
CAR T Cells Show Superiority Over Standard Therapies for RRMMDavid KillockNature Reviews Clinical Oncology2023DOI 10.1038/s41571-023-00749-y
Patient Preferences Regarding Treatment Options for Relapsed Refractory Multiple Myeloma (RRMM)Bauer, SJohn Wiley and Sons2017DOI 10.1016/j.jval.2017.08.299
Patient‐Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)Chari, AjaiAlphamed Press2019DOI 10.1634/theoncologist.2018-0724
A Patient-Physician Tool to Improve CoMMunication in Relapsed Refractory Multiple Myeloma (RRMM)Leblanc, ThomasElsevier2019DOI 10.1016/j.clml.2019.09.397
Daratumumab-Based Regimens with Prior Carfilzomib in Patients with Relapsed Refractory Multiple Myeloma (RRMM)Tungesvik, AlexandreElsevier2019DOI 10.1016/j.clml.2019.07.314
Pcn165 Slr Of Economic Evaluation For Treatment Of Relapsed/refractory Multiple Myeloma (rrmm) In UkMehta, J.John Wiley and Sons2020DOI 10.1016/j.jval.2020.04.1647
